Login to Your Account



Other News To Note


Monday, February 14, 2011
Gilead Sciences Inc., of Foster City, Calif., refiled its new drug application (NDA) for the single-tablet regimen of Truvada (emtricitabine and tenofovir disoproxil fumarate) and TMC278 (rilpivirine hydrochloride), a non-nucleoside reverse transcriptase inhibitor from Tibotec Pharmaceuticals Ld., a unit of New Brunswick, N.J.-based Johnson & Johnson.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription